Title: Treatment of newly diagnosed chronic myeloid leukemia with imatinib united homoharringtonine
Abstract: Objective To observe the curative effect,toxicity and side-effect of imatinib combined homoharringtonine(HHT) on newly diagnosed chronic myeloid leukemia(CML). Methods 33 patients were randomly divided into 2 groups,the united imatinib with HHT group had 17 cases(IM+HHT group) and imatinib single-use group 16 cases(IM group).Hematologic and cytogenetic response rates at different times of treatment were observed.Results The hematologic remission rate at third month and cytogenetic remission rate at sixth month had no significant difference,but the cytogenetic remission rate at twelfth month of IM+HHT group was higher than that in IM group.There were no significant differences of non-hematological toxicity and serious hematological toxicity between the two groups.Conclusion There is a synergistic effect between HHT and imatinib on CML and combined use of imatinib and HHT may increase the cytogenetic remission rate of newly diagnosed CML patients.
Publication Year: 2009
Publication Date: 2009-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot